Prostate Cancer Incidence 5 Years After US Preventive Services Task Force Recommendations Against Screening.
Journal
Journal of the National Cancer Institute
ISSN: 1460-2105
Titre abrégé: J Natl Cancer Inst
Pays: United States
ID NLM: 7503089
Informations de publication
Date de publication:
04 01 2021
04 01 2021
Historique:
received:
22
11
2019
revised:
03
03
2020
accepted:
07
05
2020
pubmed:
21
5
2020
medline:
22
6
2021
entrez:
21
5
2020
Statut:
ppublish
Résumé
Previous studies reported that prostate cancer incidence rates in the United States declined for local-stage disease and increased for regional- and distant-stage disease following the US Preventive Services Task Force recommendations against prostate-specific antigen-based screening for men aged 75 years and older in 2008 and for all men in 2012. It is unknown, however, whether these patterns persisted through 2016. Based on the US Cancer Statistics Public Use Research Database, we examined temporal trends in invasive prostate cancer incidence from 2005 to 2016 in men aged 50 years and older stratified by stage (local, regional, and distant), age group (50-74 years and 75 years and older), and race and ethnicity (all races and ethnicities, non-Hispanic Whites, and non-Hispanic Blacks) with joinpoint regression models to estimate annual percent changes. Tests of statistical significance are 2-sided (P < .05). For all races and ethnicities combined, incidence for local-stage disease declined beginning in 2007 in men aged 50-74 years and 75 years and older, although the decline stabilized during 2013-2016 in men aged 75 years and older. Incidence decreased by 6.4% (95% CI = 4.9%-9% to 7.9%) per year from 2007 to 2016 in men aged 50-74 years and by 10.7% (95% CI = 6.2% to 15.0%) per year from 2007 to 2013 in men aged 75 years and older. In contrast, incidence for regional- and distant-stage disease increased in both age groups during the study period. For example, distant-stage incidence in men aged 75 years and older increased by 5.2% (95% CI = 4.2% to 6.1%) per year from 2010 to 2016. Regional- and distant-stage prostate cancer incidence continue to increase in the United States in men aged 50 years and older, and future studies are needed to identify reasons for the rising trends.
Sections du résumé
BACKGROUND
Previous studies reported that prostate cancer incidence rates in the United States declined for local-stage disease and increased for regional- and distant-stage disease following the US Preventive Services Task Force recommendations against prostate-specific antigen-based screening for men aged 75 years and older in 2008 and for all men in 2012. It is unknown, however, whether these patterns persisted through 2016.
METHODS
Based on the US Cancer Statistics Public Use Research Database, we examined temporal trends in invasive prostate cancer incidence from 2005 to 2016 in men aged 50 years and older stratified by stage (local, regional, and distant), age group (50-74 years and 75 years and older), and race and ethnicity (all races and ethnicities, non-Hispanic Whites, and non-Hispanic Blacks) with joinpoint regression models to estimate annual percent changes. Tests of statistical significance are 2-sided (P < .05).
RESULTS
For all races and ethnicities combined, incidence for local-stage disease declined beginning in 2007 in men aged 50-74 years and 75 years and older, although the decline stabilized during 2013-2016 in men aged 75 years and older. Incidence decreased by 6.4% (95% CI = 4.9%-9% to 7.9%) per year from 2007 to 2016 in men aged 50-74 years and by 10.7% (95% CI = 6.2% to 15.0%) per year from 2007 to 2013 in men aged 75 years and older. In contrast, incidence for regional- and distant-stage disease increased in both age groups during the study period. For example, distant-stage incidence in men aged 75 years and older increased by 5.2% (95% CI = 4.2% to 6.1%) per year from 2010 to 2016.
CONCLUSIONS
Regional- and distant-stage prostate cancer incidence continue to increase in the United States in men aged 50 years and older, and future studies are needed to identify reasons for the rising trends.
Identifiants
pubmed: 32432713
pii: 5837113
doi: 10.1093/jnci/djaa068
pmc: PMC7781461
doi:
Substances chimiques
Prostate-Specific Antigen
EC 3.4.21.77
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
64-71Commentaires et corrections
Type : CommentIn
Type : CommentIn
Type : CommentIn
Informations de copyright
© The Author(s) 2020. Published by Oxford University Press. All rights reserved. For permissions, please email: journals.permissions@oup.com.
Références
Cancer Epidemiol Biomarkers Prev. 2017 Feb;26(2):222-227
pubmed: 27742670
Cancer. 2014 Nov 15;120(22):3519-26
pubmed: 25065910
JAMA Oncol. 2017 May 1;3(5):705-707
pubmed: 28033446
J Urol. 2018 Jun;199(6):1510-1517
pubmed: 29288121
JAMA. 2018 Apr 24;319(16):1723-1725
pubmed: 29570750
J Natl Cancer Inst. 2016 Jan 27;108(7):
pubmed: 26823525
Cancer. 2017 Jun 15;123(12):2312-2319
pubmed: 28436011
Ann Fam Med. 2018 Mar;16(2):139-144
pubmed: 29531105
Cancer. 2018 Jul 1;124(13):2801-2814
pubmed: 29786851
Ann Intern Med. 2008 Aug 5;149(3):185-91
pubmed: 18678845
Stat Methods Med Res. 2006 Dec;15(6):547-69
pubmed: 17260923
J Natl Cancer Inst. 2020 Oct 1;112(10):1013-1020
pubmed: 32067047
JAMA Oncol. 2016 Dec 1;2(12):1657-1660
pubmed: 27541955
Stat Med. 2000 Feb 15;19(3):335-51
pubmed: 10649300
CA Cancer J Clin. 2020 Jan;70(1):7-30
pubmed: 31912902
JAMA Oncol. 2015 Jun;1(3):342-9
pubmed: 26181184
J Natl Cancer Inst. 2017 Aug 1;109(8):
pubmed: 29117387
N Engl J Med. 2016 Aug 25;375(8):794-8
pubmed: 27557308
JAMA. 2018 Jun 19;319(23):2419-2429
pubmed: 29922829
Lancet Oncol. 2009 Nov;10(11):1033-4
pubmed: 19891056
JAMA. 2018 May 8;319(18):1901-1913
pubmed: 29801017
Ann Intern Med. 2012 Jul 17;157(2):120-34
pubmed: 22801674
Cancer. 2018 Jul 1;124(13):2733-2739
pubmed: 29781117
Ann Intern Med. 2013 Feb 5;158(3):145-53
pubmed: 23381039
J Natl Cancer Inst. 2002 Oct 16;94(20):1537-45
pubmed: 12381706